Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes including Actinium-225 Iodine-131 and Lutetium-177 directed at multiple targets in oncology and hematology including CD45 CD33 HER3 and other. It has collaboration with Astellas Pharma Inc. to develop theranostics for solid tumor indications; EpicentRx Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York New York.